Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term disease. Found 60 abstracts

no pagination
Yu H, Tian Y, Wang Y, Mineishi S, Zhang Y. Dendritic Cell Regulation of Graft-Vs.-Host Disease: Immunostimulation and Tolerance. Frontiers in immunology. 2019 Jan;10:93.   PMCID: PMC6367268
Liu L, Tamura K, Sanderford M, Gray VE, Kumar S. A Molecular Evolutionary Reference for the Human Variome. Molecular biology and evolution. 2016 Jan;33(1):245-54.   PMCID: PMC5009994
Agochukwu NQ, Metwalli AR, Kutikov A, Pinto PA, Linehan WM, Bratslavsky G. Economic Burden of Repeat Renal Surgery on Solitary Kidney-Do the Ends Justify the Means? A Cost Analysis. Journal of Urology. 2012 Nov;188(5):1695-700.   PMCID: PMC 3817487
Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbaecker KB, Soucy P, Beesley J, Chen XQ, Wang XS, Kirchhoff T, McGuffog L, Barrowdale D, Lee A, Healey S, Sinilnikova OM, Andrulis IL, Ozcelik H, Mulligan AM, Thomassen M, Gerdes AM, Jensen UB, Skytte AB, Kruse TA, Caligo MA, von Wachenfeldt A, Barbany-Bustinza G, Loman N, Soller M, Ehrencrona H, Karlsson P, Nathanson KL, Rebbeck TR, Domchek SM, Jakubowska A, Lubinski J, Jaworska K, Durda K, Zlowocka E, Huzarski T, Byrski T, Gronwald J, Cybulski C, Gorski B, Osorio A, Duran M, Tejada MI, Benitez J, Hamann U, Hogervorst FB, van Os TA, van Leeuwen FE, Meijers-Heijboer HE, Wijnen J, Blok MJ, Kets M, Hooning MJ, Oldenburg RA, Ausems M, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Jacobs C, Eeles RA, Adlard J, Davidson R, Eccles DM, Cole T, Cook J, Paterson J, Brewer C, Douglas F, Hodgson SV, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Side LE, Bove B, Godwin AK, Stoppa-Lyonnet D, Fassy-Colcombet M, Castera L, Cornelis F, Mazoyer S, Leone M, Boutry-Kryza N, Bressac-de Paillerets B, Caron O, Pujol P, Coupier I, Delnatte C, Akloul L, Lynch HT, Snyder CL, Buys SS, Daly MB, Terry M, Chung WK, John EM, Miron A, Southey MC, Hopper JL, Goldgar DE, Singer CF, Rappaport C, Tea MK, Fink-Retter A, Hansen TV, Nielsen FC, Arason A, Vijai J, Shah S, Sarrel K, Robson ME, Piedmonte M, Phillips K, Basil J, Rubinstein WS, Boggess J, Wakeley K, Ewart-Toland A, Montagna M, Agata S, Imyanitov EN, Isaacs C, Janavicius R, Lazaro C, Blanco I, Feliubadalo L, Brunet J, Gayther SA, Pharoah PP, Odunsi KO, Karlan BY, Walsh CS, Olah E, Teo SH, Ganz PA, Beattie MS, van Rensburg EJ, Dorfling CM, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Heinritz W, Caldes T, de la Hoya M, Muranen TA, Nevanlinna H, Tischkowitz M, Spurdle AB, Neuhausen SL, Ding YC, Lindor NM, Fredericksen Z, Pankratz VS, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Bernard L, Viel A, Giannini G, Varesco L, Radice P, Greene MH, Mai PL, Easton DF, Chenevix-Trench G, Offit K, Simard J. Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers & Prevention. 2012 Apr;21(4):645-57.   PMCID: PMC3319317
Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM. Epithelial-Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. Molecular Cancer Therapeutics. 2012 Nov;11(11):2526-34.   PMCID: PMC 3500676
Hoppe RT, Advani RH, Ai WY, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Winter JN, Yahalom J, Sundar H. Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 May;10(5):589-97.   PMCID: not NIH funded
Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer. Journal of surgical oncology. 2012 Jul;106(1):24-30.   PMCID: PMC3370134
Kamboj M, Son C, Cantu S, Chemaly RF, Dickman J, Dubberke E, Engles L, Lafferty T, Liddell G, Lesperance ME, Mangino JE, Martin S, Mayfield J, Mehta SA, O'Rourke S, Perego CS, Taplitz R, Eagan J, Sepkowitz KA. Hospital-Onset Clostridium difficile Infection Rates in Persons with Cancer or Hematopoietic Stem Cell Transplant: A C3IC Network Report. Infection Control and Hospital Epidemiology. 2012 Nov;33(11):1162-5.   PMCID: PMC 3670420
Lee CK, Marschner IC, Simes RJ, Voysey M, Egleston B, Hudes G, de Souza P. Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus. Clinical Cancer Research. 2012 Jun;18(11):3188-96.   PMCID: Not NIH funded
Nitzkorski JR, Farma JM, Watson JC, Siripurapu V, Zhu F, Matteotti RS, Sigurdson ER. Outcome and Natural History of Patients with Stage IV Colorectal Cancer Receiving Chemotherapy Without Primary Tumor Resection. Annals of Surgical Oncology. 2012 Feb;19(2):379-83.   PMCID: not NIH funded
Pro B, Perini GF. Brentuximab vedotin in Hodgkin's lymphoma. Expert Opinion on Biological Therapy. 2012 Oct;12(10):1415-21.   PMCID: Not NIH Funded
Roberts JL, Buckley RH, Luo B, Pei JM, Lapidus A, Peri S, Wei Q, Shin J, Parrott RE, Dunbrack RL, Testa JR, Zhong XP, Wiest DL. CD45-deficient severe combined immunodeficiency caused by uniparental disomy. Proceedings of the National Academy of Sciences of the United States of America. 2012 Jun;109(26):10456-61.   PMCID: PMC3387083
Skarbnik AP, Smith MR. Brentuximab vedotin in anaplastic large cell lymphoma. Expert Opinion on Biological Therapy. 2012 May;12(5):633-9.   PMCID: *
von Mehren M, Rankin C, Goldblum JR, Demetri GD, Bramwell V, Ryan CW, Borden E. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer. 2012 Feb;118(3):770-6.   PMCID: PMC3576704
Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study. Gynecologic Oncology. 2011 Oct;123(1):19-26.   PMCID: PMC3336961 [Available on 2012/10/1]
Chen KC, Xu M, Wedemeyer WJ, Roder H. Microsecond Unfolding Kinetics of Sheep Prion Protein Reveals an Intermediate that Correlates with Susceptibility to Classical Scrapie. Biophysical journal. 2011 Sep;101(5):1221-30.   PMCID: PMC3164147
Elkin EB, Klem ML, Gonzales AM, Ishill NM, Hodgson D, Ng AK, Marks LB, Weidhaas J, Freedman GM, Miller RC, Constine LS, Myrehaug S, Yahalom J. Characteristics and Outcomes of Breast Cancer in Women With and Without a History of Radiation for Hodgkin's Lymphoma: A Multi-Institutional, Matched Cohort Study. Journal of Clinical Oncology. 2011 Jun;29(18):2466-73.   PMCID: PMC3138631[Available on 2012/6/20]
Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V, Cristofanilli M. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer. 2011 Dec;117(24):5476-84.   PMCID: not NIH funded
Han ZY, Nogusa S, Nicolas E, Balachandran S, Taylor J. Interferon Impedes an Early Step of Hepatitis Delta Virus Infection. PLoS One. 2011 Jul;6(7):e22415.   PMCID: PMC3139649
Leu JI, Pimkina J, Pandey P, Murphy ME, George DL. HSP70 Inhibition by the Small-Molecule 2-Phenylethynesulfonamide Impairs Protein Clearance Pathways in Tumor Cells. Molecular Cancer Research. 2011 Jul;9(7):936-47.   PMCID: PMC3140602
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term disease

disease expression survival cancer receptor chemotherapy stem-cell transplantation mammalian target radiotherapy gene childhood antigen progression kinase marker carcinoma metastatic colorectal-cancer graft-vs-host grade 8q24 conversion non-hodgkins-lymphoma inclusion-body formation 1989 entice rl-statistics in medicine-v8-p431 dna-repair embryonic stem-cells dialysis patients micrometastases beta-subunit gemcitabine long-term survival disparities 2nd cancer platinum-resistant natural scrapie adaptation ALK ALCL-anaplastic large cell lymphoma-antibody-drug conjugate-brentuximab vedotin-CD30-MMAE-non-Hodgkin lymphoma-SGN-35-T-cell lymphoma phase-ii breast-cancer ultrarapid mixing experiments hsp90 fdg-pet factor receptor transcription factors sgn-30 randomized-trial enhancer isodisomy family mtor epithelial ovarian-cancer human epidermal growth factor receptor 2 database hemangiopericytoma metabolism alleles intermolecular disulfide bonds histone methyltransferase ezh2 angiosarcoma hematologic malignancies dendritic cells immunostimulation dexamethasone feasibility metastases 1993 nair anb-v382-p161 allelic rapamycin heat-shock proteins initial presentation free survival surgery 1995 bruin pc-leukemia-v9-p1620 estrogen proteasome inhibitors variants prostate-cancer positron-emission-tomography beliefs AKT involved-field inhibitor system colon-cancer mortality circulating tumor-cells quality-of-life ki-1 lymphoma liposarcoma sunitinib carcinomas epithelial-cells alloreactive T cells tumor subtypes tyrosine phosphatase cd45 therapeutic target inflammatory breast cancer 2 cycles abnormalities deficiency features ovarian induced apoptosis hemodialysis susceptibility loci neutrality zeste homolog-2 leiomyosarcoma heat-shock-protein-70 2007 ylor jm-p3031 esrd patients doxorubicin phase-2 solitary fibrous tumor evolution T cell receptor T lymphocyte-signaling partial nephrectomy tumors refractory age secondary structure crystal-structure neoplasm recurrence kidney-local-nephrectomy-reoperation-costs and cost analysis recurrence surrogate consequences carriers Ovarian clinical trial multicenter resistant prostate-cancer enhancer of zeste homolog 2 PI3K pathway prp outcomes entry phenotype consortium Circulating tumor cells mTOR b-virus protein brentuximab vedotin antibody-drug conjugate-CD30-Hodgkin's lymphoma-MMAE-SGN-35 1992 en bl-v31-p1464 high-dose chemoradiotherapy carcinoma patients uric-acid nephrolithiasis access peripheral-blood inhibitors bowel obstruction
Last updated on Friday, July 10, 2020